Verastem Oncology announced positive molecular profiling and external control arm analysis data from its Phase 2 RAMP 201 trial for avutometinib plus defactinib in recurrent LGSOC. The data showed clinically meaningful activity in KRAS wild-type tumors and improved outcomes versus conventional care, suggesting potential for the drug combination in a specific patient population.
Verastem Oncology (VSTM) released new, positive data from its Phase 2 RAMP 201 clinical trial for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC). The key findings include clinically meaningful activity in KRAS wild-type LGSOC, particularly in NRAS- or BRAF-mutated tumors and triple wild-type tumors, and statistically significant improvements in PFS compared to conventional care. This is a significant positive development for VSTM as it provides further evidence of the drug combination's efficacy in specific LGSOC patient subgroups, potentially expanding its market opportunity. Short-term, this could lead to increased investor confidence and a positive stock reaction. Long-term, these data support the drug's development pathway and potential for regulatory approval, offering a key opportunity for traders looking at growth in the oncology space.